Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Market Transgenomic Oncology Diagnostics Outside US

NEW YORK (GenomeWeb News) – Personalized medicine firm Transgenomic today announced that it has signed a deal under which PerkinElmer will market and distribute its portfolio of molecular diagnostic oncology products in all markets outside the US.

PerkinElmer will have non-exclusive rights to sell, market, and distribute, as well as provide field service activities, for the Transgenomic products beginning Jan. 1, 2014, with an initial launch in Europe. Included in the deal is Transgenomics' CRC RAScan kit, which detects genetic mutations helpful in guiding treatment decisions for colorectal cancer, and ACE kits for use on PerkinElmer's LabChip MultiDx platform.

The CRC RAScan kit already has the CE IVD Mark, enabling it to be marketed in Europe and other regions and countries that recognize the CE Mark. Specifically, the test detects the full range of RAS mutations that are relevant to a poor response to EGFR inhibitors.

Financial terms of the arrangement were not disclosed.

Paul Kinnon, president and CEO of Transgenomic, said in a statement that PerkinElmer is "the ideal commercial collaborator for our oncology genetic testing portfolio outside of the US. This portfolio addresses a growing breadth of genetic markers important to assessing risk, prognosis and treatment of a variety of cancers."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.